MedTrace Logo

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

NCT01631318 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-06-10

No results posted yet for this study

Summary

Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases

Conditions

Interventions

PROCEDURE

Dynamic contrast-enhanced ultrasound imaging

Ultrasound imaging procedure

DEVICE

Optical Tracking Device

Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.

DEVICE

Electromagnetic Tracking Device

Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.

DRUG

Perflutren

Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Philips Healthcare

    collaborator INDUSTRY

  • Stanford University

    lead OTHER

Principal Investigators

  • Aya Kamaya · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-01
Primary Completion
2020-08-31
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01631318 on ClinicalTrials.gov